Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI)

Manuscript Number: 

17-0149R1

Author(s): 
Robert Bartha, Sandra E. Black, Elizabeth Finger, Morris Freedman, Barry Greenberg, David A. Grimes, Robert A. Hegele, Christopher Hudson, Peter W. Kleinstiver, Anthony E. Lang, Mario Masellis, William McIlroy, Paula M. McLaughlin, Manuel Montero-Odasso, Douglas P. Munoz, Frederico Pieruccini-Faria, Michael J. Strong, Steven Strother, Rick H. Swartz, Sean Symons, Carmela Tartaglia, Lorne Zinman

Disclosures

Robert Bartha

  • Nothing to Disclose

Sandra E. Black

  • Consulting Fees:
    Novartis (<$10,000) Merck (<$10,000) Pfizer (<$10,000) Eli Lilly (<$10,000)
    Lecture Fees:
    Medscape /Biogen (<$10,000)
    Grants
    • Agency: 
      Eli Lilly
      Dates: 
      2014-2020
    • Agency: 
      Pfizer
      Dates: 
      2013-2015
    • Agency: 
      GE Healthcare
      Dates: 
      2016-2020
    • Agency: 
      Cognoptix
      Dates: 
      2016-2020
    • Agency: 
      Biogen-idec
      Dates: 
      2016-2020
    • Agency: 
      Novartis
      Dates: 
      2017-

Elizabeth Finger

  • Nothing to Disclose

Morris Freedman

  • Consulting Fees:
    I received honoraria from Eli Lilly Canada Inc for participating in consultancy and advisory board meetings
    Equity:
    I own stocks but none have any relationship with the paper
    Patents/Royalties
    I am listed on a provisional patent related to methods and kits for differential diagnosis of Alzheimer’s disease vs frontotemporal dementia using blood biomarkers and may be listed on the planned patent application.

Barry Greenberg

  • Nothing to Disclose

David A. Grimes

  • Consulting Fees:
    Honorarium for Consulting: Ipsen, Allergan
    Lecture Fees:
    Honorarium for speaking: Allergan

Robert A. Hegele

  • Nothing to Disclose

Christopher Hudson

  • Nothing to Disclose

Peter W. Kleinstiver

  • Nothing to Disclose

Anthony E. Lang

  • Consulting Fees:
    Advisory and consulting for: Abbvie, Acorda, Avanir Pharmaceuticals, Biogen, Bristol Myers Squibb, Cipla, Intekrin, and Merck
    Lecture Fees:
    Sun Pharma, Medichem, Medtronic, Teva, UCB, AbbVie and Sunovion
    Patents/Royalties
    publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press.

Mario Masellis

  • Consulting Fees:
    Consulting fees for UCB, Novartis
    Patents/Royalties
    Primary inventor on a patent owned by Teva Royalties from Henry Stewart Talks Ltd.
    Grants
    • Agency: 
      Axovant
      Dates: 
      2016-current

William McIlroy

  • Nothing to Disclose

Paula M. McLaughlin

  • Nothing to Disclose

Manuel Montero-Odasso

  • Nothing to Disclose

Douglas P. Munoz

  • Nothing to Disclose

Frederico Pieruccini-Faria

  • Nothing to Disclose

Michael J. Strong

  • Nothing to Disclose

Steven Strother

  • Equity:
    Part ownership (20% equity) of ADMdx, LLC (Chicago, USA) a company focussed on predictive modeling & image processing in dementia drug trials for big pharmaceutical companies.

Rick H. Swartz

  • Nothing to Disclose

Sean Symons

  • Lecture Fees:
    Biogen - Multiple sclerosis talk

Carmela Tartaglia

  • Nothing to Disclose

Lorne Zinman

  • Nothing to Disclose